INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology through innate immune system targeting, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The event will take place on May 20-21, 2025, at the InterContinental Barclay NY. The company will participate in a fireside chat and conduct one-on-one virtual meetings, with their presentation scheduled for 11:00 AM EDT.
INmune Bio Inc. (NASDAQ: INMB), un'azienda biotecnologica in fase clinica specializzata in infiammazione e immunologia attraverso il targeting del sistema immunitario innato, ha annunciato la sua partecipazione alla 2025 RBC Capital Markets Global Healthcare Conference. L'evento si terrà il 20-21 maggio 2025 presso l'InterContinental Barclay di New York. La società parteciperà a una tavola rotonda e terrà incontri virtuali individuali, con la presentazione programmata per le 11:00 AM EDT.
INmune Bio Inc. (NASDAQ: INMB), una empresa biotecnológica en etapa clínica enfocada en inflamación e inmunología mediante el enfoque en el sistema inmunitario innato, ha anunciado su participación en la Conferencia Global de Salud 2025 de RBC Capital Markets. El evento se llevará a cabo los días 20 y 21 de mayo de 2025 en el InterContinental Barclay de Nueva York. La compañía participará en una charla informal y realizará reuniones virtuales individuales, con su presentación programada para las 11:00 AM EDT.
INmune Bio Inc. (NASDAQ: INMB)는 선천 면역 체계 타겟팅을 통한 염증 및 면역학에 중점을 둔 임상 단계 생명공학 회사로, 2025 RBC Capital Markets 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 행사는 2025년 5월 20일~21일 뉴욕 인터컨티넨탈 바클리에서 개최됩니다. 회사는 파이어사이드 채팅에 참여하고 일대일 가상 미팅을 진행하며, 발표는 동부 표준시 오전 11시에 예정되어 있습니다.
INmune Bio Inc. (NASDAQ : INMB), une entreprise biotechnologique en phase clinique spécialisée dans l'inflammation et l'immunologie via le ciblage du système immunitaire inné, a annoncé sa participation à la conférence mondiale 2025 RBC Capital Markets Global Healthcare. L'événement aura lieu les 20 et 21 mai 2025 à l'InterContinental Barclay de New York. La société participera à une discussion informelle et tiendra des réunions virtuelles individuelles, avec une présentation prévue à 11h00 EDT.
INmune Bio Inc. (NASDAQ: INMB), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Entzündungen und Immunologie durch gezielte Ansprache des angeborenen Immunsystems spezialisiert hat, hat seine Teilnahme an der 2025 RBC Capital Markets Global Healthcare Conference angekündigt. Die Veranstaltung findet am 20. und 21. Mai 2025 im InterContinental Barclay in New York statt. Das Unternehmen wird an einem Fireside-Chat teilnehmen und Einzelgespräche virtuell führen, die Präsentation ist für 11:00 Uhr EDT geplant.
- None.
- None.
BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY.
2025 RBC Capital Markets Global Healthcare Conference
May 20-21, 2025
Format: Fireside Chat and 1-on-1 virtual meetings
Presentation Time: 11:00am EDT
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™), and INKmune®™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
David Moss
Co-founder and Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ
When is INmune Bio (INMB) presenting at the 2025 RBC Capital Markets Healthcare Conference?
Where is the 2025 RBC Capital Markets Global Healthcare Conference being held?
What type of presentation will INMB give at the RBC Healthcare Conference?
What is INmune Bio's (INMB) main business focus?
